Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age

Vaccine

Volumn 31, Issue 19, 2013, Pages 2358-2365

  Gorse, Geoffrey J ^a   Falsey, Ann R ^b   Fling, John A ^c   Poling, Terry L ^d   Strout, Cynthia B ^e   Tsang, Peter H ^f  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c UNIVERSITY OF NORTH TEXAS   (United States)

^d Heartland Research Associates   (United States)

^e Coastal Carolina Research Center ^*  (United States)

^f SANOFI PASTEUR   (France)

Author keywords

Immune response; Influenza; Vaccines

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ;

ABSCESS; ADULT; ANTIBODY TITER; ARTICLE; CHRONIC SINUSITIS; ECCHYMOSIS; ERYTHEMA; FEMALE; FEVER; GASTROESOPHAGEAL REFLUX; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; HYPOKALEMIA; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VACCINATION; INJECTION SITE PAIN; INTERVERTEBRAL DISK HERNIA; INTUSSUSCEPTION; LIMB FRACTURE; MAJOR CLINICAL STUDY; MALAISE; MALE; MICROINJECTION; MYALGIA; PRIORITY JOURNAL; PRURITUS; RASH; SEROCONVERSION; SHIVERING; SIDE EFFECT; SKIN INDURATION; STENT OCCLUSION; SWELLING; THORAX PAIN; UTERUS MYOMA; VIRUS STRAIN;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIBODY FORMATION; DOUBLE-BLIND METHOD; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PAIN; VACCINATION; YOUNG ADULT;

EID: 84876079444     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.03.008     Document Type: Article

References (37)

1. Centers for Disease Control and Prevention. Update: Influenza activity-United States, 2010-11 season, and composition of the 2011-12 influenza vaccine. MMWR 2011; 60:705-12.
2. Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2010; 59 (No.RR-8):1-62.
3. US Department of Health and Human Services. Immunization and infectious diseases. Washington, DC: US Department of Health and Human Services; 2011. Available at [accessed: 13.05.2011]. http://www.healthypeople.gov/2020/topicsobjectives2020/objectiveslist.aspx%3FtopicID=23.
4. Centers for Disease Control and Prevention. Place of influenza vaccination among adults-United States, 2010-11 influenza season. MMWR 2011; 60:781-5.
5. Centers for Disease Control and Prevention. State-specific influenza vaccination coverage among adults aged ≥18 years-United States, 2003-04, and 2005-06 influenza seasons. MMWR 2007; 56:953-9.
6. Blank P.R., Schwenkglenks M., Szucs T.D. Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive seasons. BMC Public Health 2008, 8:272.
7. Johnson D.R., Nichol K.L., Lipczynski K. Barriers to adult immunization. Am J Med 2008, 121:S28-S35.
8. Coleman P.J., Shaw F.E., Serovich J., Hadler S.C., Margolis H.S. Intradermal hepatitis B vaccination in a large hospital employee population. Vaccine 1991, 9:723-727.
9. Micozkadioglu H., Zumrutdal A., Torun D., Sezer S., Ozdemir F.N. Low dose intradermal vaccination is superior to high dose intramuscular vaccination for hepatitis B in unresponsive hemodialysis patients. Ren Fail 2007, 29:285-288.
10. Pancharoen C., Mekmullica J., Thisyakorn U., Kasempimolporn S., Wilde H., Herzog C. Reduced-dose intradermal vaccination against hepatitis A with an aluminum-free vaccine is immunogenic and can lower costs. Clin Infect Dis 2005, 41:1537-1540.
11. Lang J., Hoa D.Q., Giori N.V., et al. Immunogenicity and safety of low-dose intradermal rabies vaccination given during an Expanded Programme on Immunization session in Viet Nam: results of a comparative randomized trial. Trans R Soc Trop Med Hyg 1999, 93:208-213.
12. Halperin W., Weiss W.I., Altman R., et al. A comparison of the intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/76 (swine flu) and A/Victoria/75: report of a study and review of the literature. Am J Public Health 1979, 69:1247-1250.
13. Vien N.C., Feroldi E., Lang J. Long-term anti-rabies antibody persistence following intramuscular or low-dose intradermal vaccination of young Vietnamese children. Trans R Soc Trop Med Hyg 2008, 102:294-296.
14. Sabchareon A., Chantavanich P., Pasuralertsakul S., et al. Persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunizations with purified Vero cell rabies vaccine. Pediatr Infect Dis J 1998, 17:1001-1007.
15. WHO expert consultation on rabies. World Health Organ Tech Rep Ser 2005; 931:1-88.
16. Kenney R.T., Frech S.A., Muenz L.R., Villar C.P., Glenn G.M. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004, 351:2295-2301.
17. Belshe R.B., Newman F.K., Cannon J., et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004, 351:2286-2294.
18. Belshe R.B., Newman F.K., Wilkins K., et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 2007, 25:6755-6763.
19. Auewarakul P., Kositanont U., Sornsathapornkul P., Tothong P., Kanyok R., Thongcharoen P. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine 2007, 25:659-663.
20. Leroux-Roels I., Vets E., Freese R., et al. Seasonal influenza vaccine delivered by intradermal microinjection: a randomized controlled safety and immunogenicity trial in adults. Vaccine 2008, 26:6614-6619.
21. Beran J., Ambrozaitis A., Laiskonis A., et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomized controlled safety and immunogenicity trial. BMC Med 2009, 7:13.
22. Van Damme P., Oosterhuis-Kafeja F., Van der Wielen M., Almagor Y., Sharon O., Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009, 27:454-459.
23. Holland D., Booy R., De Looze F., et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008, 198:650-658.
24. Arnou R., Icardi G., De Decker M., et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 2009, 27:7304-7312.
25. Nicolas J.-F., Guy B. Intradermal, epidermal, and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 2008, 7:1201-1214.
26. Valladeau J., Saeland S. Cutaneous dendritic cells. Semin Immunol 2005, 17:273-283.
27. Laurent A., Mistrettag F., Bottigioli D., et al. Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines. Vaccine 2007, 25:6423-6430.
28. Laurent P.E., Bonnet S., Alchas P., et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 2007, 25:8833-8842.
29. ®) administered by intradermal and intramuscular route in healthy adults. Vaccine 2011, 29:5666-5674.
30. Advanced laboratory techniques for influenza diagnosis, Immunology series no. 6 1975, Center for Disease Control, US Department of Health, Education and Welfare, Atlanta, GA. D.F. Palmer, W.R. Dowdle, M.T. Colema, G.C. Schild (Eds.).
31. United Nations Development Programme (UNDP)/World Bank/World Health Organization (WHO) Special Programme for Research and Training in Tropical Diseases (TDR). Handbook: good laboratory practice (GLP). Available at: [accessed: 1.05.2009]. http://apps.who.int/tdr/publications/training-guideline-publications/good-laboratory-practice-handbook/pdf/glp-handbook.pdf.
32. Powers R.D., Hayden F.G., Samuelson J., Gwaltney J.M. Immune response of adults to sequential influenza vaccination. J Med Virol 1984, 14:169-175.
33. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. 9/27/2007. [accessed: 20.11.12]. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/guidances/vaccines/ucm074775.htm.
34. ®: a new intradermal vaccine for seasonal influenza. Expert Rev Vaccines 2010, 9:1399-1409.
35. Weinberger B., Herndler-Brandstetter D., Schwanninger A., Weiskopf D., Grubeck-Loebenstein B. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis 2008, 26:1078-1084.
36. Prymula R., Usluer G., Altimel S., Sichova R., Weber F. Acceptance and opinions of Intanza/ID flu intradermal influenza vaccine in the Czech Republic and Turkey. Adv Ther 2012, 29:41-52.
37. ® 9μg intradermal influenza vaccine in routine clinical practice in Australia and Argentina. Adv Ther 2011, 28:640-649.